Failure of vasodilator infusion to alter pulmonary diffusing capacity in systemic sclerosis

Craig A. Thurm, Fredrick Wigley, William P. Dole, Robert A Wise

Research output: Contribution to journalArticle

Abstract

Purpose: Patients with systemic sclerosis (SSc) do not exhibit a normal increase in the diffusing capacity for carbon monoxide (DLCO) on assuming the supine position. We sought to determine whether a potent prostacyclin derivative and vasodilator, iloprost, would reverse this defect. Patients and Methods: Fourteen patients with SSc were enrolled in a randomized, doubleblind, placebo-controlled study of iloprost. Patients were tested before and during 3 days of Uoprost or placebo infusion with both upright and supine pulmonary function studies. Results: The results of baseline pulmonary function studies including DLCO were not significantly altered by iloprost Furthermore, iloprost did not alter the abnormal postural DLCO response. Conclusion: These results suggest that the pulmonary vascular defects seen in this group of patients are not a consequence of reversible pulmonary vasospasm.

Original languageEnglish (US)
Pages (from-to)547-552
Number of pages6
JournalAmerican Journal of Medicine
Volume90
Issue number5
DOIs
StatePublished - 1991

Fingerprint

Pulmonary Diffusing Capacity
Systemic Scleroderma
Iloprost
Vasodilator Agents
Lung
Placebos
Supine Position
Epoprostenol
Carbon Monoxide
Blood Vessels

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Failure of vasodilator infusion to alter pulmonary diffusing capacity in systemic sclerosis. / Thurm, Craig A.; Wigley, Fredrick; Dole, William P.; Wise, Robert A.

In: American Journal of Medicine, Vol. 90, No. 5, 1991, p. 547-552.

Research output: Contribution to journalArticle

@article{1479d291305f43a6807265ca02d05153,
title = "Failure of vasodilator infusion to alter pulmonary diffusing capacity in systemic sclerosis",
abstract = "Purpose: Patients with systemic sclerosis (SSc) do not exhibit a normal increase in the diffusing capacity for carbon monoxide (DLCO) on assuming the supine position. We sought to determine whether a potent prostacyclin derivative and vasodilator, iloprost, would reverse this defect. Patients and Methods: Fourteen patients with SSc were enrolled in a randomized, doubleblind, placebo-controlled study of iloprost. Patients were tested before and during 3 days of Uoprost or placebo infusion with both upright and supine pulmonary function studies. Results: The results of baseline pulmonary function studies including DLCO were not significantly altered by iloprost Furthermore, iloprost did not alter the abnormal postural DLCO response. Conclusion: These results suggest that the pulmonary vascular defects seen in this group of patients are not a consequence of reversible pulmonary vasospasm.",
author = "Thurm, {Craig A.} and Fredrick Wigley and Dole, {William P.} and Wise, {Robert A}",
year = "1991",
doi = "10.1016/S0002-9343(05)80004-X",
language = "English (US)",
volume = "90",
pages = "547--552",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Failure of vasodilator infusion to alter pulmonary diffusing capacity in systemic sclerosis

AU - Thurm, Craig A.

AU - Wigley, Fredrick

AU - Dole, William P.

AU - Wise, Robert A

PY - 1991

Y1 - 1991

N2 - Purpose: Patients with systemic sclerosis (SSc) do not exhibit a normal increase in the diffusing capacity for carbon monoxide (DLCO) on assuming the supine position. We sought to determine whether a potent prostacyclin derivative and vasodilator, iloprost, would reverse this defect. Patients and Methods: Fourteen patients with SSc were enrolled in a randomized, doubleblind, placebo-controlled study of iloprost. Patients were tested before and during 3 days of Uoprost or placebo infusion with both upright and supine pulmonary function studies. Results: The results of baseline pulmonary function studies including DLCO were not significantly altered by iloprost Furthermore, iloprost did not alter the abnormal postural DLCO response. Conclusion: These results suggest that the pulmonary vascular defects seen in this group of patients are not a consequence of reversible pulmonary vasospasm.

AB - Purpose: Patients with systemic sclerosis (SSc) do not exhibit a normal increase in the diffusing capacity for carbon monoxide (DLCO) on assuming the supine position. We sought to determine whether a potent prostacyclin derivative and vasodilator, iloprost, would reverse this defect. Patients and Methods: Fourteen patients with SSc were enrolled in a randomized, doubleblind, placebo-controlled study of iloprost. Patients were tested before and during 3 days of Uoprost or placebo infusion with both upright and supine pulmonary function studies. Results: The results of baseline pulmonary function studies including DLCO were not significantly altered by iloprost Furthermore, iloprost did not alter the abnormal postural DLCO response. Conclusion: These results suggest that the pulmonary vascular defects seen in this group of patients are not a consequence of reversible pulmonary vasospasm.

UR - http://www.scopus.com/inward/record.url?scp=0025921652&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025921652&partnerID=8YFLogxK

U2 - 10.1016/S0002-9343(05)80004-X

DO - 10.1016/S0002-9343(05)80004-X

M3 - Article

C2 - 1709338

AN - SCOPUS:0025921652

VL - 90

SP - 547

EP - 552

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 5

ER -